Clinical trials
Drug-Related Side Effects and Adverse Reactions trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
104 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 2 |
| 2003 | 2 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 7 |
| 2014 | 7 |
| 2015 | 5 |
| 2016 | 7 |
| 2017 | 6 |
| 2018 | 7 |
| 2019 | 6 |
| 2020 | 11 |
| 2021 | 14 |
| 2022 | 6 |
| 2023 | 5 |
| 2024 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 104 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Samsung Medical Center | 4 |
| Anhui Medical University | 2 |
| Assaf-Harofeh Medical Center | 2 |
| Chulalongkorn University | 2 |
| Cui Yimin | 2 |
| Dokuz Eylul University | 2 |
| National Taiwan University Hospital | 2 |
| Shanghai Zhongshan Hospital | 2 |
| The Catholic University of Korea | 2 |
| University Hospital, Caen | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Drug-Related Side Effects and Adverse Reactions | 104 |
| Neoplasms | 4 |
| Agnosia | 3 |
| COVID-19 | 3 |
| Hematologic Neoplasms | 3 |
| Acute Kidney Injury | 2 |
| Breast Neoplasms | 2 |
| Carcinoma, Hepatocellular | 2 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Lung Neoplasms | 2 |
Trials
Showing 51 to 75 of 104. Each trial links to its page on Pharma Observatory.
4 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.